Literature DB >> 29091197

RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.

E K Alidjinou1, J Deldalle1, C Hallaert1, O Robineau2, F Ajana2, P Choisy2, D Hober1, L Bocket1.   

Abstract

Background: Sanger sequencing of plasma RNA is the standard method for HIV-1 drug resistance testing in treatment-naive patients, but is limited by the non-detection of resistance-associated mutations (RAMs) with prevalence below approximately 20%.
Objectives: We compared RNA and DNA Sanger sequencing (RSS and DSS) with RNA next-generation sequencing (NGS) for RAM detection in HIV-1 reverse transcriptase (RT), protease (PR) and integrase (IN) genes.
Methods: Sanger sequencing was performed on RNA and DNA, following the recommendations of the French Agency for AIDS Research (ANRS). NGS was performed on RNA using the HIV-1 Drug Resistance Assay, v. 3.0 (Roche) on the 454 GS Junior sequencer. The IAS-USA list was used to identify RAMs. ANRS, Rega and Stanford algorithms were used for drug resistance interpretation.
Results: The study included 48 ART-naive patients. The number of patients with at least one major RAM was 3, 3, 4 and 8 when using RSS, DSS, NGS 20% and NGS 5%, respectively. Numerous minor mutations were detected in patients, especially in the protease gene. None of the methods detected any major mutation in the integrase gene. Overall, the mutation detection rate was similar between RSS and DSS, and higher with NGS 20%. Differences in drug resistance interpretation were found between algorithms. No impact of the minority RAMs detected by NGS was found on the short-term treatment outcome. Conclusions: DSS does not clearly improve the detection of RAMs in ART-naive patients, as compared with RSS. NGS allows detection of additional minority RAMs; however, their clinical relevance requires further investigation.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29091197     DOI: 10.1093/jac/dkx232

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Development of a Versatile, Near Full Genome Amplification and Sequencing Approach for a Broad Variety of HIV-1 Group M Variants.

Authors:  Andrew N Banin; Michael Tuen; Jude S Bimela; Marcel Tongo; Paul Zappile; Alireza Khodadadi-Jamayran; Aubin J Nanfack; Josephine Meli; Xiaohong Wang; Dora Mbanya; Jeanne Ngogang; Adriana Heguy; Phillipe N Nyambi; Charles Fokunang; Ralf Duerr
Journal:  Viruses       Date:  2019-04-01       Impact factor: 5.048

2.  Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil.

Authors:  Kazeem Adeboyejo; Victória Riquena Grosche; Diego Pandeló José; Giulia Magalhães Ferreira; Jacqueline Farinha Shimizu; Barnabas J King; Alexander W Tarr; Márcia Maria Costa Nunes Soares; Jonathan K Ball; C Patrick McClure; Ana Carolina Gomes Jardim
Journal:  Access Microbiol       Date:  2022-03-02

3.  RNA markers for ultra-rapid molecular antimicrobial susceptibility testing in fluoroquinolone-treated Klebsiella pneumoniae.

Authors:  Xi Yang; Marjan M Hashemi; Nadya Andini; Michelle M Li; Shuzhen Kuang; Karen C Carroll; Tza-Huei Wang; Samuel Yang
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790

4.  Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting.

Authors:  Wassim Chehadeh; Osama Albaksami; Shaikhah Al-Shammari
Journal:  Antivir Chem Chemother       Date:  2020 Jan-Dec

5.  Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments.

Authors:  Andrea Arias; Pablo López; Raphael Sánchez; Yasuhiro Yamamura; Vanessa Rivera-Amill
Journal:  Int J Environ Res Public Health       Date:  2018-08-09       Impact factor: 3.390

6.  Validation of publicly-available software used in analyzing NGS data for HIV-1 drug resistance mutations and transmission networks in a Washington, DC, Cohort.

Authors:  Kamwing Jair; Chase D McCann; Harrison Reed; Amanda D Castel; Marcos Pérez-Losada; Brittany Wilbourn; Alan E Greenberg; Jeanne A Jordan
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

Review 7.  Interaction of the Host and Viral Genome and Their Influence on HIV Disease.

Authors:  Riley H Tough; Paul J McLaren
Journal:  Front Genet       Date:  2019-01-23       Impact factor: 4.599

8.  A cross-sectional study to characterize local HIV-1 dynamics in Washington, DC using next-generation sequencing.

Authors:  Keylie M Gibson; Kamwing Jair; Amanda D Castel; Matthew L Bendall; Brittany Wilbourn; Jeanne A Jordan; Keith A Crandall; Marcos Pérez-Losada
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

9.  Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing.

Authors:  Emma R Lee; Neil Parkin; Cheryl Jennings; Chanson J Brumme; Eric Enns; Maria Casadellà; Mark Howison; Mia Coetzer; Santiago Avila-Rios; Rupert Capina; Eric Marinier; Gary Van Domselaar; Marc Noguera-Julian; Don Kirkby; Jeff Knaggs; Richard Harrigan; Miguel Quiñones-Mateu; Roger Paredes; Rami Kantor; Paul Sandstrom; Hezhao Ji
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

Review 10.  Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations.

Authors:  Santiago Ávila-Ríos; Neil Parkin; Ronald Swanstrom; Roger Paredes; Robert Shafer; Hezhao Ji; Rami Kantor
Journal:  Viruses       Date:  2020-06-05       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.